Renovaro (NASDAQ:RENB) Bolsa

Renovaro Biosciences

Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.

Renovaro Inc

renBTC

DA Davidson analyst Clark Wright assumes Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Neutral rating and raises Price Target to $28.

News

Price Target

Initiation

Analyst Ratings

FIVN

DA Davidson Assumes Five9 at Neutral, Raises Price Target to $28

Offerings

SCNX

Scienture Holdings Files For Mixed Shelf Offering Of Up To $200M

TWC Enterprises (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TWC#TSX">TWC</a>) reported quarterly earnings of $0.88 per share. This is a 576.92 percent increase over earnings of $0.13 per share from the same period last year. The company reported $61.560 million in sales this quarter. This is a 1.00 percent decrease over sales of $62.183 million the same period last year.

Earnings

TSX:TWC

TWC Enterprises Q2 EPS $0.88 Up From $0.13 YoY, Sales $61.560M Down From $62.183M YoY

TTEC

TTEC Holdings CEO Kenneth Tuchman Withdraws Acquisition Proposal; CEO Not To Pursue His Previously Announced Proposal Due To Market Conditions

Buybacks

MELI

MercadoLibre Says Board Authorized Company To Buy Back Its Own Common Stock Up To A Total $4.05M

Stock Split

HCTI

Healthcare Triangle Effects 1-For-249 Reverse Stock Split

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) has outperformed the market over the past 5 years by 6.69% on an annualized basis producing an average annual return of 20.19%. Currently, Spotify Technology has a market capitalization of $129.05 billion. 
Buying $100 In SPOT: If an investor had bought $100 of SPOT stock 5 years ago, it would be worth $246.49 today based on a price of $627.15 for SPOT at the time of writing.
<h3>Spotify Technology's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754083827_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

SPOT

Here's How Much You Would Have Made Owning Spotify Technology Stock In The Last 5 Years

Compass Point analyst Merrill Ross upgrades Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Neutral to Buy and raises the price target from $22 to $24.

Upgrades

Compass Point Upgrades Independence Realty Trust to Buy, Raises Price Target to $24

<a href="https://x.com/bradlightcap/status/1951389149149405618?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/bradlightcap/status/1951389149149405618?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

MSFT

OpenAI COO Brad Lightcap Posts On X "we have surpassed 5M paying business users on chatgpt, up from 3M in june.we continue to see growth in every segment, from small startups and SMBs to fortune 500. we are working to make it easier for companies of any size to get to implementation and success quickly.."

Trump Media & Technology Q2 EPS $(0.08) Up From $(0.10) YoY, Sales $883.30K Up From $836.90K YoY

CIBC analyst Hamir Patel maintains Methanex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) with a Outperformer and raises the price target from $42 to $44.

MEOH

CIBC Maintains Outperformer on Methanex, Raises Price Target to $44

CIBC maintains Gildan Activewear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIL#NYSE">GIL</a>) with a Outperformer and raises the price target from $56 to $60.

CIBC Maintains Outperformer on Gildan Activewear, Raises Price Target to $60

Management

MVST

On July 29, Microvast Holdings  Carl T. Schultz Ceases As CFO

General

NVEE

Kodiak Gas Services Will Replace NV5 Global In The S&P Smallcap 600 Effective Prior To The Opening Of Trading On Wednesday, August 06

CIBC analyst Anita Soni maintains Kinross Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) with a Outperformer and raises the price target from $21 to $22.

CIBC Maintains Outperformer on Kinross Gold, Raises Price Target to $22

Figma Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIG#NYSE">FIG</a>) shares traded higher Friday, continuing to draw investor attention after a volatile debut session on Thursday that saw the stock surge over 250% <a href="https://www.benzinga.com/markets/equities/25/08/46785080/jim-cramer-calls-figma-too-expensive-at-50x-sales-stock-surges-250-on-market-debut">following its initial public offering. </a>
What To Know: The stock briefly reached $143.45 in after-hours trading before pulling back.
Figma priced its IPO at $33 per share, raising approximately $1.2 billion and valuing the company at over $19 billion. The offering consisted of nearly 37 million shares and was priced above an already upwardly revised range. Despite sharp gains on day one, Friday&#8217;s trading showed signs of cooling momentum as shares gave up part of their early advance.
Investor interest in Figma is being fueled by strong revenue growth and widespread enterprise adoption. The company reported $749 million in revenue for 2024, up 48% year-over-year and $228.2 million in first-quarter 2025, representing 46% growth from the year prior. Figma counts 95% of Fortune 500 companies and major tech clients such as Microsoft, Alphabet and Salesforce among its customers. It ended 2024 with a net dollar retention rate of 134%.
Still, not everyone is convinced by the valuation. 
CNBC host Jim Cramer repeatedly warned on social media that Figma was "way too expensive," trading at nearly 54 times sales based on a 40% growth rate. He advised investors to avoid placing market orders and predicted a pullback, calling it one of the most expensive stocks in the market.
Despite those warnings, the IPO defied expectations, reinforcing investor appetite for high-growth tech names amid renewed optimism in the broader tech sector. 
Figma's debut follows the collapse of a $20 billion acquisition deal by Adobe, which was scrapped due to regulatory pressure. Now trading independently, Figma has quickly become one of the most closely watched post-IPO stocks, with some market watchers suggesting it could take on meme stock status in the coming weeks.
Friday afternoon, the stock appeared to be stabilizing after its initial surge, trading modestly higher but far below its first-day peak.
FIG Price Action: Figma shares closed Friday up 5.63% at $122, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/08/46805962/trump-russia-medvedev-nuclear-submarines-vix-index-wall-street">Trump Issues Nuclear Threat To Russia–And Wall Street&#8217;s Fear Gauge Goes Vertical</a></li>
</ul>
Image Via Shutterstock.

Movers

Figma Shares Edge Higher After Explosive IPO Debut, Despite Valuation Concerns

CIBC analyst Scott Fletcher maintains Colliers International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGI#NASDAQ">CIGI</a>) with a Outperformer and raises the price target from $149 to $175.

CIGI

CIBC Maintains Outperformer on Colliers International Gr, Raises Price Target to $175

NTHI

On July 28, NeOnc Technologies Enters Subscription Agreement With Quazar And Nuromena;  Quazar To Purchase 2,500,000 Nuromena Shares For $400,000;  Co's Holding In Nuromena Reduced To 80%

ABAT

American Battery Technology Says Contract Terminated To Sell Legacy Property In Fernley, Nevada; On July 28, Purchase Agreement Terminated Without Penalties

Canaccord Genuity analyst Jeremy Hoy maintains New Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NGD#TSX">NGD</a>) with a Buy and raises the price target from C$8.25 to C$9.

TSX:NGD

Canaccord Genuity Maintains Buy on New Gold, Raises Price Target to C$9

Legal

Press Releases

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

Small Cap

Opinion

AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

Smart Healthcare Is Taking Over. Here's Where the Money's Headed

Biotech

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks

AMZN

AVAI

CCLD

CCLDO

CERT

GEHC

GOOG

GOOGL

MDAI

OMDA

POAI

RENB

TREN

Adicet Bio

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Annovis Bio

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

ImmuCell

MiNK Therapeutics

Opus Genetics

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

MediciNova

OS Therapies

Pyxis Oncology

Renovaro

Repare Therapeutics

Serina Therapeutics

Sutro Biopharma

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Screenshot 2024-05-06 at 6.05.33 PM

NVDA

Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection

Comments

Renovaro

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL